Holen Sie sich die Stockscreener-App
14.66
0.54%
-0.08
Handel nachbörslich:
14.66
Schlusskurs vom Vortag:
$14.74
Offen:
$14.66
24-Stunden-Volumen:
1.46M
Relative Volume:
1.47
Marktkapitalisierung:
$1.71B
Einnahmen:
$1.12B
Nettoeinkommen (Verlust:
$5.00M
KGV:
1,466.00
EPS:
0.01
Netto-Cashflow:
$-383.00M
1W Leistung:
+5.32%
1M Leistung:
+14.00%
6M Leistung:
+17.94%
1J Leistung:
-6.92%
1-Tages-Spanne:
$14.52
$14.90
1-Wochen-Bereich:
$13.47
$15.23
52-Wochen-Spanne:
$7.33
$15.55
Indivior Plc Stock (INDV) Company Profile
Firmenname
Indivior Plc
Sektor
Telefon
804-379-1090
Adresse
234 BATH ROAD, SLOUGH, BERKSHIRE
Vergleichen Sie INDV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INDV
Indivior Plc
|
14.66 | 1.71B | 1.12B | 5.00M | -383.00M | 0.01 |
|
RGC
Regencell Bioscience Holdings Ltd
|
14.60 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.19 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.35 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.37 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.64 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Indivior Plc Stock (INDV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-07-23 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-03 | Eingeleitet | Craig Hallum | Buy |
| 2023-07-13 | Eingeleitet | Northland Capital | Outperform |
Indivior Plc Aktie (INDV) Neueste Nachrichten
Indivior PLC Announces Changes in Major Holdings - TipRanks
Wirral Council v Indivior/Reckitt: Supreme Court refuses permission to appeal representative action strike out - stewartslaw.com
Indivior PLC Corrects Director Shareholding Disclosure - TipRanks
REGIndivior PLCDirector/PDMR ShareholdingCorrection - TradingView
Naloxone Market to Reflect Significant Incremental - openPR.com
Indivior Directors Increase Stake in Company Shares - TipRanks
Suboxone Market Set to Witness Growth as Opioid Dependency - openPR.com
Substance Abuse Treatment Market Size, Trends & Growth - openPR.com
Indivior PLC Announces Changes in Major Shareholdings - MSN
Indivior-Funded Study Suggests Opvee Outperforms Narcan. But at What? - Filter
INDV DEADLINE ALERT: Bernstein Liebhard LLP Reminds Indivior PLC Investors of Upcoming Deadline - ACCESS Newswire
Indivior PLC (INDV) Stock Analysis: Exploring a 9.21% Potential Upside Amidst Strategic Developments - DirectorsTalk Interviews
Suboxone Market Is Booming Nationwide with New Formulations - openPR.com
Shareholders that lost money on Indivior PLC(INDV) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Indivior PLC Announces Change in Major Shareholder Holdings - TipRanks
Levi & Korsinsky Notifies Shareholders of Indivior PLC(INDV) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Substance Abuse Treatment Market Set to Witness Digital and Personalized Care Expansion | Indivior, Alkermes - openPR.com
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference - GlobeNewswire Inc.
Indivior to delist from London Stock Exchange, maintain primary listing on Nasdaq - MSN
Indivior PLC (INDV) Stock Analysis: Evaluating the 17.71% Potential Upside Amidst Market Challenges - DirectorsTalk Interviews
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Indivior PLC To Contact The Firm - ACCESS Newswire
Indivior’s exit comes as no surprise - The Times
Levi & Korsinsky Notifies Indivior PLC Investors of a Class Action Lawsuit and Upcoming DeadlineINDV - ACCESS Newswire
Indivior PLC (INDV) Stock Price Down 3.27% on Jun 2 - GuruFocus
Opioid Use Disorder Market Projected to Witness Massive GrowthIndivior PLC, Alkermes plc - openPR.com
Trending tickers: The latest investor updates on Tesla, Palantir, Sanofi, Babcock and Indivior - Yahoo
Kalkine : Indivior’s Exit from London Exchange Impacts FTSE 100 Pharmaceutical Landscape - Kalkine Media
Indivior to delist from London Stock Exchangewill stay on Nasdaq - Insider Media Ltd
Drug maker Indivior joins London Stock Exchange exodus, 2 Jun 2025 11:00 - Shares Magazine
Kalkine : Indivior’s FTSE 100 Sector Shift: Delisting from London to Focus on Nasdaq Listing - Kalkine Media
Kalkine: Indivior Exits London as FTSE 100 Firm Focuses on Nasdaq - Kalkine Media
FTSE pharma giant joins London stock market exodus - The Telegraph
Indivior (INDV) Delists from London to Focus on U.S. Market - GuruFocus
Indivior brings curtain down on turbulent 11-year run in London - Proactive financial news
Indivior drops London listing to focus on U.S. market By Investing.com - Investing.com Nigeria
Indivior To Delist From LSE To Better Align With US Focused Business - Nasdaq
Indivior to cancel secondary listing in London - Sharecast.com
Indivior Plans to Cancel London Listing After Moving Primary to US - Bloomberg.com
Drug maker Indivior to abandon London stock market for the US - Yahoo
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained - GuruFocus
kalkine: FTSE 350 firm Indivior PLC (LON:INDV) to leave London listing after Nasdaq shift - Kalkine Media
Indivior to Cancel London Stock Exchange Listing, Focuses on Nasdaq - TipRanks
Indivior to Cancel Secondary Listing on London Stock Exchange, Maintains Primary Nasdaq Listing | Indivior Stock News - paginasiete.bo
Indivior to delist from London Stock Exchange, maintain Nasdaq listing - marketscreener.com
Indivior Announces Intention to Cancel Secondary Listing on Lond - GuruFocus
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained | INDV Stock News - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 1, 2024 in Indivior PLC LawsuitINDV - ACCESS Newswire
Indivior Announces Patrick Barry as Chief Commercial Officer - The Malaysian Reserve
Indivior appoints Patrick Barry as Chief Commercial Officer By Investing.com - Investing.com South Africa
Indivior Announces Patrick Barry as Chief Commercial Officer | I - GuruFocus
Indivior appoints Patrick Barry as Chief Commercial Officer - Investing.com India
Finanzdaten der Indivior Plc-Aktie (INDV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):